{
      "StudyFieldsResponse": {
            "APIVrs": "1.01.05",
            "DataVrs": "2022:10:06 23:25:58.836",
            "Expression": "mesenchymal ALLO-ASC-DFU",
            "NStudiesAvail": 430108,
            "NStudiesFound": 13,
            "MinRank": 1,
            "MaxRank": 1000,
            "NStudiesReturned": 13,
            "FieldList": [
                  "DesignTimePerspective",
                  "DesignWhoMasked",
                  "DetailedDescription",
                  "DispFirstPostDate",
                  "DispFirstPostDateType",
                  "DispFirstSubmitDate",
                  "DispFirstSubmitQCDate",
                  "EligibilityCriteria",
                  "EnrollmentCount",
                  "EnrollmentType",
                  "EventGroupDeathsNumAffected",
                  "EventGroupDeathsNumAtRisk",
                  "EventGroupDescription",
                  "EventGroupId",
                  "EventGroupOtherNumAffected",
                  "NCTId"
            ],
            "StudyFields": [
                  {
                        "Rank": 1,
                        "DesignTimePerspective": [],
                        "DesignWhoMasked": [
                              "Participant"
                        ],
                        "DetailedDescription": [
                              "ALLO-ASC-DFU is a hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells. Adipose-derived stem cells have anti-inflammatory effect and release growth factors such as vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF), which can enhance wound healing and regeneration of new tissue, finally may provide a new option in treating a Diabetic Foot Ulcer."
                        ],
                        "DispFirstPostDate": [],
                        "DispFirstPostDateType": [],
                        "DispFirstSubmitDate": [],
                        "DispFirstSubmitQCDate": [],
                        "EligibilityCriteria": [
                              "Inclusion Criteria:\n\nSubject is between 18 years and 80 years of age.\nSubject is diagnosed with Type I or Type II diabetes, and had defined as diabetic foot ulcers presence of wound for more than 4 weeks at the screening visit.\nUlcer located the foot, and ulcer size is between 1 cm^2 and 25 cm^2.\nUlcer extends into the dermis, subcutaneous tissue, tendon or joint capsule (Wagner grade 1 or 2).\nUlcer is free of necrotic debris.\n\nSubjects had adequate circulation to ulcer as documented by one of the methods below:\n\nPalpation of pulses around ulcer using Doppler exam\nAnkle Brachial index (ABI) values ranging between 0.7 and 1.3, or\nTranscutaneous Oxygen Pressure (TcPO2) > 30 mmHg.\nSubject is able to give written informed consent prior to study start and to comply with the study requirements.\n\nExclusion Criteria:\n\nUlcer is of non-diabetic pathophysiology.\nThe ulcer has increased or decreased in size by 30% or more during one week after the screening visit.\nSubject is Human Immunodeficiency Virus (HIV) positive.\nSubjects with severe hepatic deficiencies.\nSubjects with a glycated hemoglobin A1c (HbA1c) level of > 15%.\nSubject who are allergic or have a hypersensitive reaction to bovine-derived proteins or fibrin glue.\nSubjects requiring intravenous (IV) antibiotics to treat the index wound infection.\nSubjects with severe renal deficiencies that is uncontrolled by dialysis\nSubjects who are pregnant or breast-feeding.\nSubjects who are unwilling to use an \"effective\" method of contraception during the study.\nCurrent evidence of severe infection including pus drainage from the wound site.\nSubjects who have a clinically relevant history of alcohol or drugs abuse.\nSubject's blood sugar is > 450 mg/dL at postprandial.\nSubjects who are not able to understand the objective of this study or to comply with the study requirements.\nSubjects who are considered to have a significant disease which can impact the study by the investigator.\nSubjects who are considered not suitable for the study by the investigator.\nSubjects who have a history of surgery for malignant tumor within the last five years (except carcinoma in situ).\nSubjects who are currently or were enrolled in another clinical study within 60 days of screening.\nSubjects who have undergone wound treatments with cell therapy, dermal substitutes, or other biological therapies within the last 30 days.\nSubjects who are receiving oral or parenteral corticosteroids, immunosuppressive, or cytotoxic agents to unstable dosage."
                        ],
                        "EnrollmentCount": [
                              "59"
                        ],
                        "EnrollmentType": [
                              "Actual"
                        ],
                        "EventGroupDeathsNumAffected": [],
                        "EventGroupDeathsNumAtRisk": [],
                        "EventGroupDescription": [],
                        "EventGroupId": [],
                        "EventGroupOtherNumAffected": [],
                        "NCTId": [
                              "NCT02619877"
                        ]
                  },
                  {
                        "Rank": 2,
                        "DesignTimePerspective": [],
                        "DesignWhoMasked": [
                              "Participant",
                              "Investigator"
                        ],
                        "DetailedDescription": [
                              "Experimental: ALLO-ASC-DFU, Placebo Comparator: Vehicle Sheet, Study type: Interventional, Study design: Randomized, Placebo-controlled, Double-blind, Parallel-group, Multi-center Study"
                        ],
                        "DispFirstPostDate": [],
                        "DispFirstPostDateType": [],
                        "DispFirstSubmitDate": [],
                        "DispFirstSubmitQCDate": [],
                        "EligibilityCriteria": [
                              "Inclusion Criteria:\n\nSubject is between 18 and 75 years of age.\nSubject is diagnosed with Type I or Type II diabetics and has diabetic foot ulcers for longer than 4 weeks at the screening visit.\nFoot ulcer size is between 1 cm2 and 15 cm2\nUlcer graded I or II by Wagner grade, and extended to skin, tendon, and subcutaneous tissue.\nFree of necrotic debris at target ulcer\n\nAround ulcer area blood circulation should be secured to meet one of below criteria;\n\nBlood vessels around the ulcer detected by Doppler Test\n0.7 < Ankle Brachial Index(ABI) < 1.3\nTranscutaneous Oxygen Pressure, TcPO2 higher than 30 mmHg\nSubject is able to give written informed consent prior to study start and to comply with the study requirements during study.\n\nExclusion Criteria:\n\nNon-diabetic pathophysiologic ulcer.\nThe ulcer has increased or decreased in size by 30% or more during one week after the screening visit.\nSubjects requiring intravenous (IV) antibiotics to treat infection.\nCurrent evidence of infection including pus drainage from the wound site.\nSubject has a glycated hemoglobin A1c (HbA1c) level of > 15%\nSubject's blood sugar is > 450 mg/dl at postprandial.\nSubjects with severe renal failure that cannot be managed by renal dialysis.\nSubjects with severe hepatic deficiencies.\nSubject is Human Immunodeficiency Virus (HIV) positive.\nSubject who has allergic or hypersensitive reaction to bovine-derived proteins or fibrin glue.\nSubject who is pregnant or breast-feeding.\nSubjects who are unwilling to use an \"effective\" method of contraception during the study.\nSubjects who have a clinically relevant history of alcohol or drugs abuse.\nSubjects who are not able to understand the objective of this study or to comply with the study requirements.\nSubjects who are considered to have a significant disease which can impact the study by investigator.\nSubjects who are considered not suitable for the study by investigator.\nSubjects who had had a history of surgery for malignant tumor within the last five years (except carcinoma in situ).\nSubjects who are currently or are enrolled in another clinical study within 60 days of screening.\nSubjects who have undergone wound treatments with growth factors, dermal substitutes, or other biological therapies within the last 30 days.\nSubjects who are receiving oral or parenteral corticosteroids, immunosuppressive, or cytotoxic agents with unstable dose prior to 4 weeks from screening.\nSubjects not comply with off-loading procedure"
                        ],
                        "EnrollmentCount": [
                              "164"
                        ],
                        "EnrollmentType": [
                              "Anticipated"
                        ],
                        "EventGroupDeathsNumAffected": [],
                        "EventGroupDeathsNumAtRisk": [],
                        "EventGroupDescription": [],
                        "EventGroupId": [],
                        "EventGroupOtherNumAffected": [],
                        "NCTId": [
                              "NCT03370874"
                        ]
                  },
                  {
                        "Rank": 3,
                        "DesignTimePerspective": [
                              "Prospective"
                        ],
                        "DesignWhoMasked": [],
                        "DetailedDescription": [
                              "This is an open-label follow up study to evaluate the safety for the subjects with ALLO-ASC-DFU treatment in phase 1 clinical trial (ALLO-ASC-DFU-101) for 23 months.\n\nALLO-ASC-DFU is a hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells. Adipose-derived stem cells have anti-inflammatory effect and release growth factors such as vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF), which can enhance wound healing and regeneration of new tissue, finally may provide a new option in treating a Diabetic Foot Ulcer."
                        ],
                        "DispFirstPostDate": [],
                        "DispFirstPostDateType": [],
                        "DispFirstSubmitDate": [],
                        "DispFirstSubmitQCDate": [],
                        "EligibilityCriteria": [
                              "Inclusion Criteria:\n\nSubjects who are treated with ALLO-ASC-DFU sheet in phase 1 clinical trial of ALLO-ASC-DFU-101.\nSubjects who are able to give written informed consent prior to study start and to comply with the study requirements.\n\nExclusion Criteria:\n\n1. Subjects who are considered not suitable for the study by the principal investigator (For example, Subjects requiring surgical procedure on target site)."
                        ],
                        "EnrollmentCount": [
                              "4"
                        ],
                        "EnrollmentType": [
                              "Actual"
                        ],
                        "EventGroupDeathsNumAffected": [],
                        "EventGroupDeathsNumAtRisk": [],
                        "EventGroupDescription": [],
                        "EventGroupId": [],
                        "EventGroupOtherNumAffected": [],
                        "NCTId": [
                              "NCT03183726"
                        ]
                  },
                  {
                        "Rank": 4,
                        "DesignTimePerspective": [],
                        "DesignWhoMasked": [],
                        "DetailedDescription": [
                              "ALLO-ASC-DFU is a hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells. Adipose-derived stem cells have anti-inflammatory effect and release growth factors such as vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF), which can enhance wound healing and regeneration of new tissue, finally may provide a new option in treating Deep Second-degree burn wounds."
                        ],
                        "DispFirstPostDate": [],
                        "DispFirstPostDateType": [],
                        "DispFirstSubmitDate": [],
                        "DispFirstSubmitQCDate": [],
                        "EligibilityCriteria": [
                              "Inclusion Criteria:\n\nSubject is 18 years of age and older.\nSubjects who have deep second-degree burn wound \u2265100cm^2.\nTBSA(Total burn surface area) \u2264 30%\nNegative for Urine beta-HCG for women of childbearing age.\nSubject is able to give written informed consent prior to study start and comply with the study requirements.\n\nExclusion Criteria:\n\nSubject who have been enrolled in another clinical study within 30 days of screening.\nSubjects who are allergic or have a hypersensitive reaction to bovine-derived proteins or fibrin glue.\nSubjects who are receiving steroids, immunosuppressive, or anticoagulant for long term\nSubjects with active infection.\nSubjects with hemorrhagic and hemocoagulative disease.\nSubjects who are unwilling to use an \"effective\" method of contraception during the study.\nSubjects who have a history of malignant tumor within the last five years, or is currently undergoing.\nSubjects who are pregnant or breast-feeding.\nSubjects who are considered to have a significant disease which can impact the wound healing by the investigator\nBurn wound is present on any part of the face.\nSubjects who are considered not suitable for the study by the investigator.\nSubjects who are not able to understand the objective of this study or to comply with the study requirements"
                        ],
                        "EnrollmentCount": [
                              "22"
                        ],
                        "EnrollmentType": [
                              "Anticipated"
                        ],
                        "EventGroupDeathsNumAffected": [],
                        "EventGroupDeathsNumAtRisk": [],
                        "EventGroupDescription": [],
                        "EventGroupId": [],
                        "EventGroupOtherNumAffected": [],
                        "NCTId": [
                              "NCT02619851"
                        ]
                  },
                  {
                        "Rank": 5,
                        "DesignTimePerspective": [
                              "Prospective"
                        ],
                        "DesignWhoMasked": [],
                        "DetailedDescription": [
                              "This is an open-label follow up study to evaluate the safety for the subjects with ALLO-ASC-DFU treatment in phase 2 clinical trial (ALLO-ASC-DFU-201) for 23 months.\n\nALLO-ASC-DFU is a hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells. Adipose-derived stem cells have anti-inflammatory effect and release growth factors such as vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF), which can enhance wound healing and regeneration of new tissue, finally may provide a new option in treating a Diabetic Foot Ulcer."
                        ],
                        "DispFirstPostDate": [],
                        "DispFirstPostDateType": [],
                        "DispFirstSubmitDate": [],
                        "DispFirstSubmitQCDate": [],
                        "EligibilityCriteria": [
                              "Inclusion Criteria:\n\nSubjects who are treated with ALLO-ASC-DFU sheet in phase 2 clinical trial of ALLO-ASC-DFU-201.\nSubjects who are able to give written informed consent prior to study start and to comply with the study requirements.\n\nExclusion Criteria:\n\n1. Subjects who are considered not suitable for the study by the principal investigator."
                        ],
                        "EnrollmentCount": [
                              "54"
                        ],
                        "EnrollmentType": [
                              "Anticipated"
                        ],
                        "EventGroupDeathsNumAffected": [],
                        "EventGroupDeathsNumAtRisk": [],
                        "EventGroupDescription": [],
                        "EventGroupId": [],
                        "EventGroupOtherNumAffected": [],
                        "NCTId": [
                              "NCT03183804"
                        ]
                  },
                  {
                        "Rank": 6,
                        "DesignTimePerspective": [],
                        "DesignWhoMasked": [
                              "Participant",
                              "Investigator"
                        ],
                        "DetailedDescription": [
                              "Active Group: ALLO-ASC-SHEET\nControl Group: Hydrogel SHEET (vehicle control)\nStudy Type: Interventional\nStudy Design: Randomized, Comparator-controlled, Double-blind, multi-center study."
                        ],
                        "DispFirstPostDate": [],
                        "DispFirstPostDateType": [],
                        "DispFirstSubmitDate": [],
                        "DispFirstSubmitQCDate": [],
                        "EligibilityCriteria": [
                              "Inclusion Criteria:\n\nMale or female subjects between 18 and 80 years of age.\nDiagnosed with Type I or Type II diabetics and has diabetic foot ulcers for longer than 4 weeks at the screening visit.\nFoot ulcer located in the instep, border or sole of the foot, with ulcer size between 1 cm2 and 15 cm2.\nUlcer graded I by Wagner grade, and extended to skin, subcutaneous tissue, but without exposure of muscle, tendon, bone or joint capsule.\nUlcer is free of necrotic debris, exhibits no signs of clinical infection.\n\nUlcer area blood circulation meets one of the following criteria\n\nA. Blood vessels around the ulcer detected by Doppler Test\nB. range of Ankle Brachial Index(ABI) was > 0.7 to < 1.3\nC. Transcutaneous oxygen pressure, (TcPO2) > 30 mmHg.\nIs able to give written informed consent prior to study start and to comply with the study requirements.\n\nExclusion Criteria:\n\nUlcer is of non-diabetic pathophysiology.\nThe ulcer has increased or decreased in size by \u2265 30% during the week after the Screening Visit.\nIs Human Immunodeficiency Virus (HIV) positive?\nHave severe hepatic deficiencies.\nHave a glycated hemoglobin A1c (HbA1c) level of > 10%.\nHave allergic or hypersensitive reaction to bovine-derived proteins or fibrin glue.\nRequire intravenous (IV) antibiotics to treat the target wound infection.\nHave severe renal failure including subject on renal dialysis.\nPregnant or breast-feeding.\nIs unwilling to use an \"effective\" method of contraception during the study.\nHave evidence of current infection including pus drainage from the wound site.\nHave a clinically relevant history of alcohol or drugs abuse.\nHave postprandial blood sugar > 350 mg/dl.\nIs not able to understand the objective of this study or to comply with the study requirements.\nIs considered by the investigator to have a significant disease which might have impacted the study.\nIs considered not suitable for the study by investigator.\nHave a history of malignancy within the last five years (except basal cell carcinoam in situ).\nIs currently or were enrolled in another clinical study within 60 days of screening.\nHave undergone wound treatments with growth factors, dermal substitutes, or other biological therapies within the last 30 days.\nIs receiving oral or parenteral corticosteroids, immunosuppressive, or cytotoxic agents with unstable dose prior to 4 weeks from screening.\nCannot maintain off-loading process\nPanel reactive antibody (PRA) levels \u2265 20%"
                        ],
                        "EnrollmentCount": [
                              "56"
                        ],
                        "EnrollmentType": [
                              "Anticipated"
                        ],
                        "EventGroupDeathsNumAffected": [],
                        "EventGroupDeathsNumAtRisk": [],
                        "EventGroupDescription": [],
                        "EventGroupId": [],
                        "EventGroupOtherNumAffected": [],
                        "NCTId": [
                              "NCT03754465"
                        ]
                  },
                  {
                        "Rank": 7,
                        "DesignTimePerspective": [],
                        "DesignWhoMasked": [],
                        "DetailedDescription": [
                              "ALLO-ASC-DFU is a hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells. Adipose-derived stem cells have anti-inflammatory effect and release growth factors such as vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF), which can enhance wound healing and regeneration of new tissue, finally may provide an new option in treating a Dystrophic Epidermolysis Bullosa."
                        ],
                        "DispFirstPostDate": [],
                        "DispFirstPostDateType": [],
                        "DispFirstSubmitDate": [],
                        "DispFirstSubmitQCDate": [],
                        "EligibilityCriteria": [
                              "Inclusion Criteria:\n\nAge : 10~60\nDiagnosed with Dystrophic Epidermolysis Bullosa based on immunofluorescence test.\nBullous skin lesion sized over 10 cm^2\nTest negative for Serum \u03b2-HCG pregnancy test on screening, if the subject is fertile\nA subject who is willing to follow the protocol and provide a informed consent on screening, given that the information with respect to the clinical trial is provided.\n\nExclusion Criteria:\n\nA subject with history of epidermoid carcinoma within a year from screening.\nA subject who requires antibiotics due to bacterial infection on skin.\nA subject who was dosed with oral steroid, over 0.5mg/kg a day for subjects under 18, or over 20mg in 2 weeks for subjects over 18, within 30 days prior to screening.\nA subject treated with radiotherapy or immunosuppressants, within 30 days prior to screening.\nA subject treated with steroids locally, within 30 days prior to screening.\nA subject with 2-times the maximum-standardized value of ALT, AST, ALP, bilirubin, total protein\nA subject with 2-times the maximum-standardized value of BUN, Creatinine\nA subject with Albumin below 2.0 g/dL.\nA subject with Hemoglobin below 6 g/dL (anemic).\nA subject with allergic response to bovine derived protein and fibrin glue.\nA subject administered with biologic agents or cell therapy, within 30 days prior to screening.\nA subject administered with stem cell treatment by IV or subcutaneously to the target wound, prior to the trial\nA subject who enrolled into another clinical trial, within 30 days prior to screening\nA subject with serious disease that can affect on clinical trial.\nA pregnant or breast-feeding subject.\nA subject with history of drug abuse within 1 year of clinical significance\nA subject who cannot proceed according to the protocol."
                        ],
                        "EnrollmentCount": [
                              "5"
                        ],
                        "EnrollmentType": [
                              "Anticipated"
                        ],
                        "EventGroupDeathsNumAffected": [],
                        "EventGroupDeathsNumAtRisk": [],
                        "EventGroupDescription": [],
                        "EventGroupId": [],
                        "EventGroupOtherNumAffected": [],
                        "NCTId": [
                              "NCT02579369"
                        ]
                  },
                  {
                        "Rank": 8,
                        "DesignTimePerspective": [],
                        "DesignWhoMasked": [],
                        "DetailedDescription": [],
                        "DispFirstPostDate": [],
                        "DispFirstPostDateType": [],
                        "DispFirstSubmitDate": [],
                        "DispFirstSubmitQCDate": [],
                        "EligibilityCriteria": [
                              "Inclusion Criteria:\n\nSubject is between 18 and 80 years of age.\nSubject is diagnosed with Type I or Type II diabetes.\nSubjects who have a wound defined as diabetic foot ulcer presence for more than 4 weeks, but not present for more than 54 weeks at the screening visit.\nFoot ulcer located below the malleoli on plantar or dorsal surface of the foot and ulcer size is between 1 cm^2 and 25 cm^2.\nUlcer extends into the dermis or subcutaneous tissue without evidence of exposed muscle, tendon, bone, or joint capsule.\nUlcer is free of necrotic debris, exhibits no signs of clinical infection, and appears to be made of primarily vascularized tissue.\n0.7 < Ankle Brachial Index (ABI) < 1.3.\nSubject is able to give written informed consent prior to study start and to comply with the study requirements.\n\nExclusion Criteria:\n\nUlcer is of non-diabetic pathophysiology.\nGangrene is present on any part of the affected foot.\nUlcer is over an active Charcot deformity.\nThe ulcer has increased or decreased in size by 30% or more during one week after the screening visit.\nThe longest dimension of the Index Ulcer exceeds 5 cm at the screening visit.\nSubject is Human Immunodeficiency Virus (HIV) positive.\nSubjects with severe hepatic deficiencies.\nSubjects with a glycated hemoglobin A1c (HbA1c) level of > 12%.\nSubject who are allergic or have a hypersensitive reaction to bovine-derived proteins or fibrin glue.\nSubjects requiring intravenous (IV) antibiotics to treat the index wound infection.\nSubjects who are currently receiving dialysis.\nSubjects who are pregnant or breast-feeding.\nSubjects who are unwilling to use an \"effective\" method of contraception during the study.\nCurrent evidence of osteomyelitis, cellulitis, or other evidence of infection including pus drainage from the wound site.\nSubjects who have a clinically relevant history of alcohol or drugs abuse.\nSubject's blood sugar is > 450 mg/dL at postprandial.\nSubjects who are not able to understand the objective of this study or to comply with the study requirements.\nSubjects who are considered to have a significant disease which can impact the study by the investigator.\nSubjects who are considered not suitable for the study by the investigator.\nSubjects who have a history of surgery for malignant tumor within the last five years (except carcinoma site).\nSubjects who are currently or were enrolled in another clinical study within 60 days of screening.\nSubjects who have undergone wound treatments with growth factors, dermal substitutes, or other biological therapies within the last 30 days.\nSubjects who are receiving oral or parenteral corticosteroids, immunosuppressive, or cytotoxic agents."
                        ],
                        "EnrollmentCount": [
                              "5"
                        ],
                        "EnrollmentType": [
                              "Actual"
                        ],
                        "EventGroupDeathsNumAffected": [],
                        "EventGroupDeathsNumAtRisk": [],
                        "EventGroupDescription": [],
                        "EventGroupId": [],
                        "EventGroupOtherNumAffected": [],
                        "NCTId": [
                              "NCT02394886"
                        ]
                  },
                  {
                        "Rank": 9,
                        "DesignTimePerspective": [
                              "Prospective"
                        ],
                        "DesignWhoMasked": [],
                        "DetailedDescription": [
                              "This is an open-label follow up study to evaluate the safety for the subjects with ALLO-ASC-DFU treatment in phase 1 clinical trial (ALLO-ASC-BI-101) for 23 months.\n\nALLO-ASC-DFU is a hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells. Adipose-derived stem cells have anti-inflammatory effect and release growth factors such as vascular endothelial growth factor(VEGF) and hepatocyte growth factor (HGF), which can enhance wound healing and regeneration of new tissue, finally may provide a new option in treating a burn."
                        ],
                        "DispFirstPostDate": [],
                        "DispFirstPostDateType": [],
                        "DispFirstSubmitDate": [],
                        "DispFirstSubmitQCDate": [],
                        "EligibilityCriteria": [
                              "Inclusion Criteria:\n\nSubjects who are treated with ALLO-ASC-DFU sheet in phase 1 clinical trial of ALLO-ASC-BI-101.\nA subject who is willing to follow the protocol and provide informed consent on screening, given that the information with respect to the clinical trial is provided.\n\nExclusion Criteria:\n\n1. Subjects who are considered not suitable for the study by the principal investigator. (For example, Subjects requiring surgical procedure on target site)"
                        ],
                        "EnrollmentCount": [
                              "5"
                        ],
                        "EnrollmentType": [
                              "Actual"
                        ],
                        "EventGroupDeathsNumAffected": [],
                        "EventGroupDeathsNumAtRisk": [],
                        "EventGroupDescription": [],
                        "EventGroupId": [],
                        "EventGroupOtherNumAffected": [],
                        "NCTId": [
                              "NCT03183622"
                        ]
                  },
                  {
                        "Rank": 10,
                        "DesignTimePerspective": [],
                        "DesignWhoMasked": [],
                        "DetailedDescription": [],
                        "DispFirstPostDate": [],
                        "DispFirstPostDateType": [],
                        "DispFirstSubmitDate": [],
                        "DispFirstSubmitQCDate": [],
                        "EligibilityCriteria": [
                              "Inclusion Criteria:\n\nSubject is 18 years of age and older.\nSubjects who have deep second-degree burn \u2265100 cm^2.\nNegative for urine beta-HCG for women of childbearing age.\nSubject is able to give written informed consent prior to study start and to comply with the study requirements.\n\nExclusion Criteria:\n\nSubjects who have been enrolled in another clinical study within 30 days of screening.\nSubjects who are allergic or have a hypersensitive reaction to bovine-derived proteins or fibrin glue.\nSubjects who are receiving steroids, immunosuppressive, or anticoagulant.\nSubjects with active infection.\nSubjects with hemorrhagic and hemocoagulative disease\nSubjects who are unwilling to use an \"effective\" method of contraception during the study.\nSubjects who have a history of malignant tumor within the last five years, or is currently undergoing.\nSubjects who are pregnant or breast-feeding.\nSubjects who are considered to have a significant disease which can impact the study by the investigator\nBurn wound is present on any part of the face.\nSubjects who have a history of surgery for malignant tumor within the last five years (except carcinoma site).\nSubjects who are considered not suitable for the study by the investigator.\nSubjects who are not able to understand the objective of this study or to comply with the study requirements."
                        ],
                        "EnrollmentCount": [
                              "5"
                        ],
                        "EnrollmentType": [
                              "Actual"
                        ],
                        "EventGroupDeathsNumAffected": [],
                        "EventGroupDeathsNumAtRisk": [],
                        "EventGroupDescription": [],
                        "EventGroupId": [],
                        "EventGroupOtherNumAffected": [],
                        "NCTId": [
                              "NCT02394873"
                        ]
                  },
                  {
                        "Rank": 11,
                        "DesignTimePerspective": [],
                        "DesignWhoMasked": [
                              "Participant",
                              "Investigator"
                        ],
                        "DetailedDescription": [
                              "Experimental: ALLO-ASC-DFU, Placebo Comparator: Vehicle Sheet, Study type: Interventional, Study design: Randomized, Placebo-controlled, Double blind, Parallel-group, Multi-center Study"
                        ],
                        "DispFirstPostDate": [],
                        "DispFirstPostDateType": [],
                        "DispFirstSubmitDate": [],
                        "DispFirstSubmitQCDate": [],
                        "EligibilityCriteria": [
                              "Inclusion Criteria:\n\nSubject is between 19 and 75 years of age.\nSubject is diagnosed with Type I or Type II diabetics.\nDiabetic foot ulcer has been more than 4 weeks but less than 52 weeks at the screening visit.\nUlcer located in the foot and ulcer size is between 1.5~15 cm2.\nUlcer graded 2 by Wagner grade.\nFoot ulcer extended to ligament, tendon, joint capsule, fascia, muscle and periosteum.\nUlcer is free of necrotic debris.\n\nUlcer area blood circulation meets one of the following criteria;\n\nBlood vessels around the ulcer detected by Doppler Test\nRange of Ankle Brachial Index (ABI) is > 0.7 to < 1.3\nTranscutaneous Oxygen Pressure (TcPO2) > 30mmHg or Toe Blood Pressure (TBP) > 40mmHg.\nSkin Perfusion Pressure (SPP) > 30mmHg\nSubject is able to give written informed consent prior to study start and willing to comply with the study requirements.\n\nExclusion Criteria:\n\nUlcer is of non-diabetic pathophysiology.\nThere is gangrene in any part of the target foot ulcer.\nThe longest dimension of the target foot ulcer exceeds 15 cm at the enrollment visit.\nOther wounds within 2cm of the target foot ulcer.\nThe ulcer has increased or decreased in size by \u2265 30% during two weeks after the screening visit.\nPatient requiring intravenous (IV) antibiotics to treat foot wound infection at the screening and enrollment visit.\nCurrent evidence of active charcot on the study foot, osteomyelitis, cellulitis, or evidence of other infection including fever or purulent drainage from wound site.\nPatient with skin lesion confirmed by biopsy (when Investigator deems suspicious) and then judged by Investigator to be an etiology other than diabetic foot ulcer.\nAn active malignant tumor(malignant melanoma, squamous cell carcinoma, basal cell carcinoma) on the body or skin.\nHave a glycated hemoglobin A1c (HbA1c) level of > 14%\nHave random blood sugar > 450mg/dL\nHave severe renal failure with creatinine > 3.0mg/dL.\n\nHave severe hepatic deficiencies\n\nTotal bilirubin \u2265 1.5\u00d7upper normal limit(UNL)\nAST, ALT \u2265 2.0\u00d7UNL\nSerum albumin < 2.0mg/dL\nIs Human Immunodeficiency Virus (HIV) positive\nHave a known history of allergic or hypersensitive reaction to bovine-derived proteins or fibrin glue\nPregnant or breast-feeding.\nIs unwilling to use an acceptable method of birth control during the whole study.\nHave a clinically relevant history of alcohol or drugs abuse at the screening visit.\nIs not able to understand the objective of the study or to comply with the study requirements\nIs considered by the Investigator to have a significant disease which might impact the study\nIs considered not suitable for the study by Investigator\nHave a history of malignancy within the last 5 years (except carcinoma in situ)\nIs currently or were enrolled in another clinical study within 60 days of screening\nHave undergone wound treatments with growth factors, dermal substitutes, or other biological therapies within the last 30 days.\nIs receiving oral or parenteral corticosteroids, any immunosuppressive, or cytotoxic agents with unstable dose within the last 30 days\nCannot maintain off-loading process and device."
                        ],
                        "EnrollmentCount": [
                              "104"
                        ],
                        "EnrollmentType": [
                              "Anticipated"
                        ],
                        "EventGroupDeathsNumAffected": [],
                        "EventGroupDeathsNumAtRisk": [],
                        "EventGroupDescription": [],
                        "EventGroupId": [],
                        "EventGroupOtherNumAffected": [],
                        "NCTId": [
                              "NCT04569409"
                        ]
                  },
                  {
                        "Rank": 12,
                        "DesignTimePerspective": [
                              "Prospective"
                        ],
                        "DesignWhoMasked": [],
                        "DetailedDescription": [
                              "This is an open-label follow up study to evaluate the safety for the subjects with ALLO-ASC-DFU treatment in phase 2 clinical trial (ALLO-ASC-BI-201) for 23 months.\n\nALLO-ASC-DFU is a hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells. Adipose-derived stem cells have anti-inflammatory effect and release growth factors such as vascular endothelial growth factor(VEGF) and hepatocyte growth factor (HGF), which can enhance wound healing and regeneration of new tissue, finally may provide a new option in treating a burn."
                        ],
                        "DispFirstPostDate": [],
                        "DispFirstPostDateType": [],
                        "DispFirstSubmitDate": [],
                        "DispFirstSubmitQCDate": [],
                        "EligibilityCriteria": [
                              "Inclusion Criteria:\n\nSubjects who are treated with ALLO-ASC-DFU sheet in phase 2 clinical trial of ALLO-ASC-BI-201.\nA subject who is willing to follow the protocol and provide informed consent on screening, given that the information with respect to the clinical trial is provided.\n\nExclusion Criteria:\n\n1. Subjects who are considered not suitable for the study by the principal investigator."
                        ],
                        "EnrollmentCount": [
                              "30"
                        ],
                        "EnrollmentType": [
                              "Anticipated"
                        ],
                        "EventGroupDeathsNumAffected": [],
                        "EventGroupDeathsNumAtRisk": [],
                        "EventGroupDescription": [],
                        "EventGroupId": [],
                        "EventGroupOtherNumAffected": [],
                        "NCTId": [
                              "NCT03183648"
                        ]
                  },
                  {
                        "Rank": 13,
                        "DesignTimePerspective": [
                              "Prospective"
                        ],
                        "DesignWhoMasked": [],
                        "DetailedDescription": [
                              "This is an open-label follow up study to evaluate the efficacy and safety for the subjects with ALLO-ASC-DFU treatment in phase 1/2 clinical trial (ALLO-ASC-EB-101) for 24 months.\n\nALLO-ASC-DFU is a hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells. Adipose-derived stem cells have anti-inflammatory effect and release growth factors such as vascular endothelial growth factor(VEGF) and hepatocyte growth factor (HGF), which can enhance wound healing and regeneration of new tissue, finally may provide a new option in treating a Dystrophic Epidermolysis Bullosa."
                        ],
                        "DispFirstPostDate": [],
                        "DispFirstPostDateType": [],
                        "DispFirstSubmitDate": [],
                        "DispFirstSubmitQCDate": [],
                        "EligibilityCriteria": [
                              "Inclusion Criteria:\n\nSubjects who are treated with ALLO-ASC-DFU sheet in phase 1/2 clinical trial of ALLO-ASC-EB-101.\nA subject who is willing to follow the protocol and provide informed consent on screening, given that the information with respect to the clinical trial is provided.\n\nExclusion Criteria:\n\n1. Subjects who are considered not suitable for the study by the principal investigator."
                        ],
                        "EnrollmentCount": [
                              "5"
                        ],
                        "EnrollmentType": [
                              "Anticipated"
                        ],
                        "EventGroupDeathsNumAffected": [],
                        "EventGroupDeathsNumAtRisk": [],
                        "EventGroupDescription": [],
                        "EventGroupId": [],
                        "EventGroupOtherNumAffected": [],
                        "NCTId": [
                              "NCT03183934"
                        ]
                  }
            ]
      }
}